Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin
- PMID: 37243544
- DOI: 10.1093/bjd/ljad184
Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin
Abstract
Background: Treatment for the debilitating disease hidradenitis suppurativa (HS) is inadequate in many patients. Despite an incidence of approximately 1%, HS is often under-recognized and underdiagnosed, and is associated with a high morbidity and poor quality of life.
Objectives: To gain a better understanding of the pathogenesis of HS, in order to design new therapeutic strategies.
Methods: We employed single-cell RNA sequencing to analyse gene expression in immune cells isolated from involved HS skin vs. healthy skin. Flow cytometry was used to quantify the absolute numbers of the main immune populations. The secretion of inflammatory mediators from skin explant cultures was measured using multiplex and enzyme-linked immunosorbent assays.
Results: Single-cell RNA sequencing analysis identified a significant enrichment in the frequency of plasma cells, T helper (Th) 17 cells and dendritic cell subsets in HS skin, and the immune transcriptome was distinct and more heterogeneous than healthy skin. Flow cytometry revealed significantly increased numbers of T cells, B cells, neutrophils, dermal macrophages and dendritic cells in HS skin. Genes and pathways associated with Th17 cells, interleukin (IL)-17, IL-1β and the NLRP3 inflammasome were enhanced in HS skin, particularly in samples with a high inflammatory load. Inflammasome constituent genes principally mapped to Langerhans cells and a subpopulation of dendritic cells. The secretome of HS skin explants contained significantly increased concentrations of inflammatory mediators, including IL-1β and IL-17A, and culture with an NLRP3 inflammasome inhibitor significantly reduced the secretion of these, as well as other, key mediators of inflammation.
Conclusions: These data provide a rationale for targeting the NLRP3 inflammasome in HS using small-molecule inhibitors that are currently being tested for other indications.
© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists.
Conflict of interest statement
Conflicts of interest: R.H. has received honoraria from AbbVie, Janssen and UCB, and has acted as a subinvestigator in clinical trials for AbbVie and UCB. K.H.G.M. is the co-founder of and a shareholder in a startup biotechnology company involved in the development of anti-inflammatory therapeutics. B.K. has received grants and/or honoraria from AbbVie, Almirall, AstraZeneca, Biogen, Bristol Myers Squibb, Celgene, Janssen, Lilly, LEO Pharma, Merck, Moonlake, Novartis, Pfizer and UCB Pharma. J.M.F. has received honoraria from Novartis and Moonlake. M.R. is a former employee of AbbVie. B.M., C.M.S., A.Z., J.K., R.W.D., K.M.S., J.M., A.P., A.F., M.O’D., K.H., W.J.H. and D.C.W. declare no conflicts of interest.
Comment in
-
The interleukin-1 pathway as a treatment target in early-stage hidradenitis suppurativa?Br J Dermatol. 2023 Sep 15;189(4):365-366. doi: 10.1093/bjd/ljad225. Br J Dermatol. 2023. PMID: 37427780 No abstract available.
-
Gaining a better understanding of the causes of hidradenitis suppurativa.Br J Dermatol. 2023 Sep 15;189(4):e77. doi: 10.1093/bjd/ljad290. Br J Dermatol. 2023. PMID: 37713516 No abstract available.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases